First Director Named for NHGRIs New Division of Genomics and Society
Lawrence C. Brody, PhD, a pioneering genetics and genomics researcher, has been selected to be the first director of the newly established Division of Genomics and Society at the National Human Genome Research Institute (NHGRI). Dr Brody is currently chief of the Genome Technology Branch within NHGRI’s intramural research programme, and the chief scientific officer of the trans-NIH Center for Inherited Disease Research. NHGRI is one of the 27 institutes and centers that make up the National Institutes of Health.
Dr Brody’s expertise and interests are wide-ranging, from human genetics and genomics to the public understanding of science. As a bench scientist, he played an instrumental role in early and important discoveries about the BRCA1 gene, which is responsible for a hereditary form of breast cancer. His research efforts have regularly included studying the practical implications of genomic advances. For example, Dr Brody was a co-architect of the NHGRI Multiplex Initiative, an innovative project that aimed to better understand how the general public comprehends and reacts to personal genetic testing results.
Dr Brody has also invested a considerable amount of his professional efforts to addressing the broader societal issues relevant to contemporary genomics research. He has worked on several projects related to genomics, society, and minority populations and, most recently, he served as a key developer of the public exhibition, Genome: Unlocking Life’s Code, which opened in June at the Smithsonian Institution’s National Museum of Natural History. Moreover, on multiple occasions, he worked closely with the US Solicitor General in the drafting and editing of legal briefs and in the preparation of oral arguments for the gene patenting case that went before the US Supreme Court earlier this year.
“Dr Brody brings an extraordinary and diverse body of accomplishments and expertise to lead this newly created division,” said NHGRI Director Eric D. Green, MD, PhD. “His perspective as a bench scientist combined with a demonstrated long-term interest in the intersection of science and society makes him uniquely qualified to lead this critical part of NHGRI’s research programme.”
The Division of Genomics and Society was established in 2012 as part of an institute-wide reorganisation. It is one of four divisions that make up the institute’s extramural research programme. This new division is now responsible for an expanded programme related to the many societal issues relevant to genomics research and genomic advances, incorporating and extending the activities of NHGRI’s Ethical, Legal and Social Implications (ELSI) research programme. The latter was established in 1990 as part of the Human Genome Project and aims to pursue multidisciplinary research and training designed to explore the impact of genomics on society.
“It is an exciting time for genetics and genomics, but with that comes the responsibility to examine and address the many important societal implications of these research advances. With improvements in technology as the driving force, genomics can increasingly be used in clinical settings in a way that was simply not possible a decade ago,” Dr Brody said. “Because genomics is moving closer to our daily lives, we need to better understand its societal impact. Issues such as consent, privacy, and access to genomic information will continue to grow in importance. We need to increasingly pursue research to understand these issues and to engage relevant stakeholders, including the general public, in the discussions.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance